HOX THERAPEUTICS LIMITED

KT21 2NP (South East)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£392,949

Dec 18 - Nov 19

Preclinical toxicological evaluation of HTL-001, a novel cancer therapeutic agent targeting HOX genes

Innovate UK award to HOX THERAPEUTICS LIMITED and Karl Keegan

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}